Assessment of endothelial dysfunction: Focus on atherothrombotic disease

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 256-261

  Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Circulating endothelial cells; Endothelial cell; Flow mediated dilatation; Soluble E selectin; Von Willebrand factor

Indexed keywords

BIOCHEMICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; NITRIC OXIDE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; BLOOD FLOW; BLOOD PRESSURE; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERTENSION; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STROKE; THROMBOCYTE; THROMBOSIS; VASODILATATION;

ENDOTHELIUM, VASCULAR; HUMANS; THROMBOSIS; VASCULAR DISEASES;

EID: 14044271443     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083811     Document Type: Conference Paper

References (49)

1. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 1994;16:901-906.
2. Henderson AH. Endothelium in control. Br Heart J 1991:65;116-125.
3. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995:90;244-248.
4. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferneres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004;109:1343-1348.
5. Borawski J, Naumnik B, Mysliwiec M. Circulating endothelial markers and probability of stroke in haemodialysis patients. Blood Coagul Fibrinolysis 2003;14:315-317.
6. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002;23:1764-1770.
7. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107:3141-3145.
8. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999;353:1729-1734.
9. Gerdes VE, Kremer Hovinga JA, Ten Cate H, Brandjes DP, Buller HR. Soluble thrombomodulin in patients with established atherosclerosis. J Thromb Haemost 2004;2:200-201.
10. Hwang SJ, Ballantyne CM, Sharret AR, Smith LC, Davis CE, Gotto A, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1. and E-selectin in carotid atherosclerosis and incident coronary heart disease. Circulation 1997;96:4219-4225
11. Blann AD, Miller JP, McCollum CN. Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997;32:151-156.
12. Blann AD, Waite MA. Von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coronary Art Dis 1996;7:143-147.
13. Galen FX. Cell adhesion molecules in hypertension: endothelial markers of vascular injury and predictors of target organ damage? J Hypertens 2002;20:813-816.
14. Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-1165
15. Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Hematol 1997;59:115-120.
16. O'Malley T, Ludlam CA, Riemersa RA, Fox KAA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. Eur Heart J 2001;22:1226-1234.
17. Hillis GS, Terrgino C, Taggart P, Killian A, Zhao N, Dalsey WC, Mangione A. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischaemia. Am Heart J 2002;143:235-241.
18. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999;20:1039-1043.
19. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001;85:623-627.
20. Porsch-Oezcueruemez M, Kunz D, Kloer HU, Luley C. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. J Am Coll Cardiol 1999;34:1995-2001.
21. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-1342.
22. Malik I, Danesh J, Whincup P. Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358:971-975.
23. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
24. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051.
25. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
26. Vallance P, Vhan N. Endothelial function and nitric oxide: clinical relevance. Heart 2001:856;342-350.
27. Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? JACC 1997:30;325-333.
28. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003;42:1149-1160
29. Felmeden DC, Blann AD, Spencer CGC, Beevers DG, Lip GYH. A comparison of flow mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and the effects of treatment. Blood Coag Fibrinolysis 2003:14;425-431.
30. Dignat-George F, Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol 2000:65;215-220.
31. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997;337:1584-1590.
32. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999;93:2951-2958.
33. Janssens D, Michiels C, Guillaume G, Cuisinier B, Louagie Y, Remacle J. Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. J Cardiovasc Pharmacol 1999;33:7-11.
34. Dang A, Wang B, Li W, Zhang P, Liu G, Zheng D, Ruan Y, Liu L. Plasma endothelin-1 levels and circulating endothelial cells in patients with aortoarteritis. Hypertens Res 2000;23:541-544.
35. Kas-Deelen AM, Harmsen MC, De Maar EF, Oost-Kort WW, Tervaert JW, Van Der Meer J, Van Son WJ, The TH. Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM-1 in blood. Kidney Int 2000;58:2533-2542.
36. Kas-Deelen AM, de Maar EF, Harmsen MC, Driessen C, van Son WJ, The TH. Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection. J Infect Dis 2000;181:721-724.
37. Mutunga M, Fulton B, Bullock R, Batchelor A, Gascoigne A, Gillespie JI, Baudouin SV. Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 2001;163:195-200.
38. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-3661.
39. Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 2001;44:1203-1208.
40. Popa ER, Kas-Deelen AM, Hepkema BG, van Son WJ, The TW, Harmsen MC. Donor-derived circulating endothelial cells after kidney transplantation. Transplantation 2002;74;1320-1327.
41. Woywodt A, Schroeder M, Gwinner W, Mengel M, Jaeger M, Schwarz A, Haller H, Haubitz M. Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 2003;76:1-4.
42. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003;361:206-210.
43. Bull TM, Golpon H, Hebbel RP, Solovey A, Cool CD, Tuder RM, Geraci MW, Voelkel NF. Circulating endothelial cells in pulmonary hypertension. Thromb Haemost 2003;90:698-703.
44. Makin A, Chung NAY, Silverman SH, Blann A, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Eur Heart J 2004;25:371-376.
45. Woywodt A, Scheer J, Hambach L, Buchholz S, Ganser A, Haller H, Hertenstein B, Haubitz M. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004;103:3603-3605.
46. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
47. Quilici J, Banzet N, Paule P, Meynard JB, Mutin M, Bonnet JL, et al. Circulating endothelial cells count as a diagnostic marker for non-ST elevation acute coronary syndromes. Circulation 2004; 110:1586-1591
48. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, Von Willenbrand Factor, interleukin 6 and prognosis in patients with acute coronary syndromes. Blod 2004 sep 16 [Epub ahead of print]
49. Chong AY, Blan D, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in gongestive heart failure. Relation of flow mediated dilation to circulaing endothelial cells, plasma indexes of endothelial damage and brain natriuretic pepide. Circulation 2004;101:1794-1798.